Videos
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Lung Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early Relapse Guides Use of CAR T Vs Other Options in LBCL
2
Sacituzumab Govitecan: Elevating Quality of Life in First-Line TNBC
3
Dr Mayer on Giredestrant's Success in Early Breast Cancer
4
Sacituzumab Govitecan Safety: Manageable AEs in First-Line TNBC Therapy
5
